Your browser doesn't support javascript.
loading
[New European approval: Brexucabtagene autoleucel in adult relapsed/refractory acute lymphoblastic leukemia]. / Nouvelle AMM: le brexucabtagene autoleucel pour les leucémies aiguës lymphoblastiques B de l'adulte en rechute ou réfractaires.
Lemoine, Jean; Marchand, Tony.
Affiliation
  • Lemoine J; AP-HP, Hématologie, Paris, France; Université Paris Cité, Paris, France; CHU Pontchaillou, service d'hématologie clinique, Rennes, France.
  • Marchand T; CHU Pontchaillou, service d'hématologie clinique, Rennes, France; Université Rennes 1, Rennes, France. Electronic address: tony.marchand@chu-rennes.fr.
Bull Cancer ; 109(12): 1232-1233, 2022 12.
Article in Fr | MEDLINE | ID: mdl-36270817
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Precursor Cell Lymphoblastic Leukemia-Lymphoma / Receptors, Chimeric Antigen Limits: Adult / Humans Language: Fr Journal: Bull Cancer Year: 2022 Document type: Article Affiliation country: France Country of publication: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Precursor Cell Lymphoblastic Leukemia-Lymphoma / Receptors, Chimeric Antigen Limits: Adult / Humans Language: Fr Journal: Bull Cancer Year: 2022 Document type: Article Affiliation country: France Country of publication: France